TCIM
RGLS

TIAA CREF Investment Management’s Regulus Therapeutics RGLS Stock Holding History

TIAA CREF Investment Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,027
Closed -$203K – 3167
2017
Q1 		$203K Hold
1,027
– – ﹤0.01% 2989
2016
Q4 		$277K Sell
1,027
-18
-2% -$5.85K ﹤0.01% 2991
2016
Q3 		$414 Hold
1,045
– – ﹤0.01% 2926
2016
Q2 		$362K Buy
1,045
+286
+38% +$205K ﹤0.01% 2988
2016
Q1 		$631K Hold
759
– – ﹤0.01% 2705
2015
Q4 		$794K Sell
759
-45
-6% -$45.1K ﹤0.01% 2711
2015
Q3 		$631K Hold
804
– – ﹤0.01% 2812
2015
Q2 		$1.06M Buy
804
+393
+96% +$634K ﹤0.01% 2668
2015
Q1 		$836K Buy
411
+56
+16% +$122K ﹤0.01% 2718
2014
Q4 		$683K Sell
355
-30
-8% -$53.4K ﹤0.01% 2852
2014
Q3 		$315K Sell
385
-15
-4% -$12.7K ﹤0.01% 3055
2014
Q2 		$386K Buy
400
+74
+23% +$63.4K ﹤0.01% 3050
2014
Q1 		$353K Hold
326
– – ﹤0.01% 3024
2013
Q4 		$289K Hold
326
– – ﹤0.01% 3058
2013
Q3 		$369K Buy
326
+26
+9% +$30.7K ﹤0.01% 3002
2013
Q2 		$353K Buy
+300
New +$285K ﹤0.01% 3009

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TIAA CREF Investment Management's RGLS Position: Q2 2017 in Review

TIAA CREF Investment Management sold out of Regulus Therapeutics (RGLS) in Q2 2017, closing a stake of 1,027 shares — an estimated $203K sold.

TIAA CREF Investment Management first reported a position in RGLS in Q2 2013 and held it in 16 quarters. The position peaked at $1.06M in Q2 2015. 46 funds tracked by Wall St. Rank hold RGLS as of Q2 2017.

  • TIAA CREF Investment Management reported no remaining Regulus Therapeutics position as of Q2 2017 after selling out during the quarter.
  • TIAA CREF Investment Management sold 1,027 Regulus Therapeutics shares in Q2 2017, an estimated $203K.
  • TIAA CREF Investment Management first reported a position in Regulus Therapeutics in Q2 2013 and held it in 16 quarters.
  • TIAA CREF Investment Management's Regulus Therapeutics position peaked at $1.06M in Q2 2015.
  • 46 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2017.

Based on TIAA CREF Investment Management's 13F filing for Q2 2017, filed 10 Aug 2017.